SCHEMBL13360783

SCHEMBL13360783

C=C1CCc2c(-c3cccc(F)c3C)nc3[nH]nc(N)c3c2C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHA4 P54764 2/20 0.34
KDR P35968 7/20 0.33
KIT P10721 5/20 0.33
FLT3 P36888 5/20 0.33
ILK Q13418 1/20 0.32
NUDT1 P36639 1/20 0.32
LCK P06239 4/20 0.32
CSF1R P07333 4/20 0.32
FLT1 P17948 4/20 0.32
DYRK1A Q13627 2/20 0.32
DAPK3 O43293 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
ABL1 P00519 1/20 0.32
NTRK1 P04629 1/20 0.32
RET P07949 1/20 0.32
IGF1R P08069 1/20 0.32
MET P08581 1/20 0.32
PDGFRB P09619 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13360769 0.89 HTR7 (0.38) EPHA4KDRKITFLT3LCK
SCHEMBL13329333 0.86 EPHA4 (0.45) EPHA4KDRKITFLT3ILK
SCHEMBL13360811 0.82 EPHA4 (0.36) EPHA4MAP2K1TYMS
SCHEMBL13360787 0.82 EPHA4 (0.53) EPHA4KDRFLT3ILKLCK
SCHEMBL13360793 0.82 HRH3 (0.37) EPHA4KDRCSF1RPRKD3MAP4K4
SCHEMBL13360782 0.81 EPHA4 (0.45) EPHA4ILK
SCHEMBL13360788 0.81 EPHA4 (0.48) EPHA4KDRABL1MAPK14
SCHEMBL13329567 0.80 EPHA4 (0.36) EPHA4KDRKITFLT3ILK
SCHEMBL13360842 0.80 EGFR (0.37) EPHA4
SCHEMBL13360819 0.78 PIK3CD (0.37) KDRKITFLT3LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113415-A1 EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER MERCK SHARP & DOHME CORP 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113415-A1 EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER EPHA4, EPHA1, ERBB4 EPHA4 1/4885KDR 41/4885KIT 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.